Your Cart Is Empty!
The LAMEA oncology drugs market is segmented into therapeutic modalities, cancer types and countries. Therapeutic modalities segment is further categorized into chemotherapy, targeted therapy, immunotherapy (biologic therapy), hormonal therapy and others. The LAMEA oncology drugs market is expected to reach $17,072.2 million by 2021. Patent expiration of key anti-cancer drugs such as Herceptin (Patent Expiration: EU-2014; US-2019), Erbitux (Patent Expiration: EU-2014; US-2016), Rituxan (Patent Expiration: EU-2013; US-2018) and Avastin (Patent Expiration: EU-2018; US-2019), is expected to boost the growth of cancer biosimilars market by 2021. Further, the biological therapy is the fastest growing segment at a CAGR of 12.2%, throughout the analysis period, on account of high efficacy and target specific action. Moreover, blood cancer drugs market was the largest revenue generating application segment in 2015, owing to the high cost of drugs (immunotherapies), used for the treatment of blood cancer.
Based on countries the LAMEA region is segmented into nine countries named Brazil, Argentina, Nigeria, South Africa, Iraq, Iran, Algeria, Saudi Arabia and Egypt. Brazil dominates the LAMEA market closely followed by Argentina, owing to rising incidence of cancer, high expenditure and gross national income (GNI) of Brazil specifically. In addition, LAMEA market is poised to grow at a promising CAGR of 8.6% during the forecast period. This high growth rate is majorly attributed to the increasing awareness towards advanced therapies, namely immunotherapies and increase in per capita healthcare spending.
The key companies profiled in the report include Amgen Inc., AstraZeneca Plc., Roche Diagnostics, GlaxoSmithKline PLC, Merck & Co., Novartis AG, AbbVie Inc. Sanofi, EIMC United Pharmaceuticals (EUP) and Actavis plc.
The report provides quantitative analysis of the current market and estimations through 2014-2021 that assists in identifying the prevailing market opportunities.
The report helps in understanding the strategies adopted by various companies for gaining market share in the anti-cancer drugs market.
The report provides a comprehensive analysis of factors that drive and restrict the growth of the LAMEA anti-cancer drugs market.
Market conditions of anti-cancer drugs market across LAMEA region are comprehensively analyzed.
Competitive intelligence highlights the business practices followed by leading market players across various geographies.
SWOT analysis enables to study the internal environment of the leading companies for strategy formulation.
LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET KEY SEGMENTS:
LAMEA oncology/anti-cancer drugs market is segmented into therapeutic modalities, cancer types and countries.
By Therapeutic modalities
Immunotherapy (Biologic Therapy)
By Cancer Types
Other LAMEA countries
Following are different modes of Licenses.
a. Single User License:
This license allows only one person to use the report. This person can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people. Unless you purchase a Site License or a Global Site License, a Single User License must be purchased for every single person that wishes to use the report within the same enterprise.
b. Single Site License:
This license allows unlimited users to use the report within one company location, e.g. a regional office. These users can use the report on any computer and may take print outs of the report but must take care of not sharing the report (or any information contained therein) with any other individual or people.
c. Global Site License:
A Global Site License (or Enterprise wide Site License or Global License) is a license granted to original purchaser, who can share a report with other employees and authorized Users of the same organization.
1. How do you deliver the reports?
The delivery of reports is depends on format & mode of license of report(s). Following are different kinds of formats of report(s) and their delivery options :
a. Electronic Format – Through email from Publisher
Report will be sent to your username email address in PDF, Excel, PowerPoint or any other electronic / softcopy format by publisher.
Delivery Time: 12 to 48 hours [depending on time difference or occurrences of national holidays]
b. Hard Copy or Printed Format or CD-Rom – Through Mail or Courier from Publisher
Report will be sent through mail / courier delivery to your shipping address by publisher.
Delivery Time: Less than, few weeks [depending on time difference or occurrences of national holidays]
2. How can I make payment for publications I purchase?
You could be able to make the payment, in following ways:
a. Online Secure Payment through Credit Card Payment : We accept Visa, Master, AMEX Cards & CCAvenue
b. Transfer of fund to our bank account via Bank transfer or Wire transfer
c. Payment via DD or Cheque
3. Is it safe to use my credit card on MarketinfoResearch?
Your personal information and online tranaction on Marketinfo Research is secure, private, and tamper-proof. All credit card payments are processed through secure and trusted payment gateways.